Pain (0-3 scale) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Sucralfate suspension (topical) showed no clear difference in pain (0-3 scale) compared with placebo suspension; GRADE not reported.
1 finding from 1 review
Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Global aphthae count and pain score · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Matsuda 2003 (rebamipide 300 mg daily vs placebo, 35 patients; high risk of reporting bias; concomitant treatments): authors stated that rebamipide improved the global evaluation aphthae count and global evaluation…
1 study · 35 participants
GRADE not reported
Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
SoF (topical interventions vs placebo), grouped comment spanning all four listed outcomes (verbatim): "5 placebo-controlled trials evaluated topical interventions (sucralfate suspension (2 trials), interferon-alpha (2…
Studies not reported
GRADE not reported
Total ulcer burden · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomesInterferon-alpha dose comparison
Kilic 2009 (interferon-alpha 1000 IU vs 2000 IU lozenges, 84 patients): the data presented did not allow analysis; authors reported no statistically significant difference in total ulcer burden between the two doses.
1 study · 84 participants
GRADE not reported
Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Hamuryudan 1998: significant adverse effects including severe sedation, polyneuropathy, loss of libido, and weight gain; a greater number of adverse events was seen for the higher (300 mg) dose; 4 patients withdrew due…
1 study · 101 participants
GRADE not reported
Number of painful days · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Sucralfate suspension (topical) showed no clear difference in number of painful days compared with placebo suspension; GRADE not reported.
1 finding from 1 review
Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Alpsoy 2002: high rate of adverse events including alopecia, leukopenia, and diarrhoea; 18 of 23 patients in the treatment arm experienced mild flu-like symptoms.
1 study · 50 participants
GRADE not reported
Adverse effects of long‐term use of available topical agents · HIV‐infected adults (> 13 years of age, per CDC) with one or more painful intraoral aphthous ulcers
The review found no eligible studies for this question.
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · HIV‐infected adults (> 13 years of age, per CDC) with one or more painful intraoral aphthous ulcers
The review found no eligible studies for this question.
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · HIV‐infected adults (> 13 years of age, per CDC) with one or more painful intraoral aphthous ulcers
The review found no eligible studies for this question.
1 finding from 1 review
Healing of ulceration · HIV‐infected adults (> 13 years of age, per CDC) with one or more painful intraoral aphthous ulcers
The review found no eligible studies for this question.
1 finding from 1 review
Incidence and recurrence after healing of ulcers · HIV‐infected adults (> 13 years of age, per CDC) with one or more painful intraoral aphthous ulcers
The review found no eligible studies for this question.
1 finding from 1 review
Healing of ulceration · HIV‐infected adults (> 13 years of age, per CDC) with one or more painful intraoral aphthous ulcers
The review found no eligible studies for this question.
1 finding from 1 review
Healing of ulceration · HIV‐infected adults (> 13 years of age, per CDC) with one or more painful intraoral aphthous ulcers
The review found no eligible studies for this question.
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · HIV‐infected adults (> 13 years of age, per CDC) with one or more painful intraoral aphthous ulcers
The review found no eligible studies for this question.
1 finding from 1 review
Incidence and recurrence after healing of ulcers · HIV‐infected adults (> 13 years of age, per CDC) with one or more painful intraoral aphthous ulcers
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects of long‐term use of available topical agents · HIV‐infected adults (> 13 years of age, per CDC) with one or more painful intraoral aphthous ulcers
The review found no eligible studies for this question.
1 finding from 1 review
Incidence and recurrence after healing of ulcers · HIV‐infected adults (> 13 years of age, per CDC) with one or more painful intraoral aphthous ulcers
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects of long‐term use of available topical agents · HIV‐infected adults (> 13 years of age, per CDC) with one or more painful intraoral aphthous ulcers
The review found no eligible studies for this question.
1 finding from 1 review